drugset / Trial / NCT03163576

The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis

NCT03163576 ↗

Phase 4 Unknown 150 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Hyperphosphatemia is a common complication of end-stage renal disease and particularly affects haemodialysis patients. Elevated serum phosphorus contributes to the development of secondary hyperparathyroidism, Mineral bone disorders,metastatic calcifications and calcific uremic arteriolopathy. There is a significant association between hyperphosphatemia and increased morbidity and mortality in end stage renal disease patients including cardiovascular morbidity and mortality ,also it's associated with hospitalization of haemodialysis patients.

Timeline

Start
2017-06
Primary completion
2019-06
Completion
2019-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 750 mg —
Subject Niacin Small molecule 2000 mg —
Background Lanthanum Unknown — —
Background Sevelamer Other / unclassified — —

Indications